生长抑素联合奥美拉唑针剂治疗轻症急性胰腺炎的临床疗效及对患者炎症因子水平的影响  

Clinical efficacy of somatostatin combined with omeprazole injection in the treatment of mild acute pancreatitis and its influence on the levels of inflammatory factors in patients

作　　者：李翔[1] 崔建华[1] LI Xiang;CUI Jianhua(Department of Gastroenterology,People's Hospital of Dongtai City,Dongtai,Jiangsu,224200,China)

机构地区：[1]东台市人民医院消化科,江苏东台224200

出　　处：《当代医学》2024年第10期44-47,共4页Contemporary Medicine

摘　　要：目的探讨生长抑素联合奥美拉唑针剂治疗轻症急性胰腺炎(AP)的临床疗效及对患者炎症因子水平的影响。方法选取2019年5月至2021年5月东台市人民医院收治的120例轻症AP患者作为研究对象,随机分为对照组与观察组,每组60例。对照组给予常规治疗+奥美拉唑针剂,观察组在对照组的基础上联合生长抑素治疗。比较两组临床疗效、炎症因子[超敏C反应蛋白(hs-CRP)、降钙素原(PCT)、WBC]水平、趋化因子[单核细胞趋化因子蛋白1(MCP-1)、不规则趋化因子(FKN)、中性粒细胞趋化因子(CINC)]水平、Ranson评分及不良反应发生情况。结果观察组治疗总有效率为95.00%,高于对照组的81.67%,差异有统计学意义(P<0.05)。治疗后,两组hs-CRP、WBC、PCT、MCP-1、FKN、CINC水平及Ranson评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论生长抑素联合奥美拉唑针剂治疗AP疗效显著,可减轻患者炎症反应,缓解病情,且未明显增加不良反应,值得临床推广应用。Objective To explore the clinical efficacy of somatostatin combined with omeprazole injection in the treatment of mild acute pancreatitis(AP)and its influence on levels of inflammatory factors in patients.Methods 120 patients with mild AP who were treated in the People's Hospital of Dongtai City from May 2019 to May 2021 were selected as the research subjects,and they were randomly divided into the control group and the observation group.The control group received conventional therapy combined with omeprazole injection,while the observation group was combined with somatostatin therapy on the basis of the control group.The clinical efficacy,inflammatory factors(hypersensitive C-reactive protein[hs-CRP],procalcitonin[PCT],WBC),chemokines(monocyte chemokine protein-1[MCP-1],fractalkine[FKN],cytokine-induced neutrophil chemoattractant[CINC]),Ranson score and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.00%,which was higher than 81.67%in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of hs-CRP,WBC,PCT,MCP-1,FKN and CINC and Ranson score of the two groups were lower than those before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05).There were no statistical differences in the adverse reactions between the two groups.Conclusion Somatostatin combined with omeprazole injection has significant efficacy in the treatment of mild AP,and can alleviate the inflammatory response and relieve the disease condition,and it does not significantly increase adverse reactions,which is worthy of clinical promotion and application.

关 键 词：生长抑素 奥美拉唑针剂 急性胰腺炎 炎症因子水平 

分 类 号：R576[医药卫生—消化系统]